Notwithstanding promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable opposition from managed care entities. The organizations are typically building limitations to reimbursement, including high price criteria and PA that limit user availability. Industry ind